What's Happening?
Sensei Biotherapeutics has dosed the first patient in a Phase 1b/2 trial of PIKTOR, an investigational treatment for HR+/HER2- advanced breast cancer. PIKTOR is an all-oral combination of serabelisib and sapanisertib, designed to inhibit multiple nodes
of the PI3K/AKT/mTOR pathway, which is often altered in HR+/HER2- cases. The trial, known as Study FTH-PIK-101, is a multi-center, dose-escalation study evaluating the safety and efficacy of PIKTOR in combination with other anticancer therapies. This trial follows a previous Phase 1b study where PIKTOR showed promising results in patients with advanced breast, endometrial, and ovarian tumors.
Why It's Important?
The initiation of this trial is crucial as it addresses a significant unmet need for patients with HR+/HER2- advanced breast cancer, particularly those whose tumors are driven by the PI3K/AKT/mTOR pathway. Current treatments often target only one component of this pathway, allowing cancer to reroute its growth signals. PIKTOR's approach of targeting multiple nodes simultaneously could offer a more effective treatment option. The trial's success could lead to a new standard of care for this subset of breast cancer patients, potentially improving outcomes and survival rates.
What's Next?
As the trial progresses, researchers will monitor the safety and efficacy of PIKTOR in combination with other therapies. If successful, the trial could lead to further studies and eventual regulatory approval, providing a new treatment option for patients with limited alternatives. Sensei Biotherapeutics is also conducting a separate Phase 2 study of PIKTOR in patients with advanced endometrial cancer, indicating a broader application of this treatment approach. The results of these trials will be closely watched by the medical community and could influence future cancer treatment strategies.
